Atazanavir in pregnancy: Impact on neonatal hyperbilirubinemia

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 157, Issue 1, 2011, Pages 18-21

  Mandelbrot, Laurent ^a,b,c   Mazy, Fabienne ^a,d   Floch Tudal, Corinne ^a   Meier, Françoise ^a   Azria, Elie ^b,d   Crenn Hebert, Catherine ^a   Treluyer, Jean Marc ^e   Herinomenzanahary, Evelyne ^a   Ferreira, Claudia ^a   Peytavin, Gilles ^d  

^a HÔPITAL LOUIS MOURIER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d BICHAT HOSPITAL   (France)

^e HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Atazanavir; HIV; Neonatal hyperbilirubinemia; Placental transfer; Pregnancy

Indexed keywords

ATAZANAVIR; BILIRUBIN; RITONAVIR;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN JAUNDICE; OBSERVATIONAL STUDY; PREGNANCY; PRIORITY JOURNAL; SIDE EFFECT;

EID: 79958785544     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2011.02.005     Document Type: Article

References (23)

1. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008;22:289-99.
2. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458-65.
3. Blanche S, Tardieu M, Benhammou V, Warszawski J, Rustin P. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 2006;20(13):1685-90. (Pubitemid 44299359)
4. Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis 2006;194(8):1089-97. (Pubitemid 44547648)
5. Public Health Service Task Force Recommendations. Use of antiretroviral drugs in pregnant hiv-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. http://www.aidsinfo. nih.gov/guidelines/, last accessed Feb 15, 2010.
6. Yeni P, editor. Prise en charge médicale des personnes infectées par le VIH. Paris: La Documentation Française; 2010.
7. Torti C, Lapadula G, Antinori A, et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection 2009;37(3):244-9.
8. Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33(November (11)):1729-39.
9. Rayner CR, Esch LD, Wynn HE, Eales R. Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen. Ann Pharmacother 2001;35:1391-5.
10. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 2004;56(November (5)):682-9.
11. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007;21(November (18)):2409-15. (Pubitemid 350145172)
12. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114(July (1)):297-316.
13. Serrano MA, Bayón JE, Pascolo L, et al. Evidence for carrier-mediated transport of unconjugated bilirubin across plasma membrane vesicles from human placental trophoblast. Placenta 2002;23(7):527-35. (Pubitemid 41110472)
14. McDonagh AF, Palma LA, Schmid R. Reduction of biliverdin and placental transfer of bilirubin and biliverdin in the pregnant guinea pig. Biochem J 1981;194(1):273-82. (Pubitemid 11152276)
15. Smith DE, Jeganathan S, Ray J. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials 2006;7:34-8.
16. Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007;21(1):41-6. (Pubitemid 44912535)
17. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004;43(15):1071-87. (Pubitemid 40013177)
18. Mirochnick M, Stek A, Capparelli E, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. In: 17th conference on retroviruses and opportunistic infections; 2010. Paper # 941.
19. Ripamonti D, Cattaneo D, d'Avolio A, et al. Steady state pharmacokinetic of ritonavir-boosted atazanavir in 31 pregnant women before and after delivery. In: 17th conference on retroviruses and opportunistic infections; 2010. Paper # 907.
20. Conradie F, Zorilla C, Josipovic D, et al. The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182. In: Program and abstracts of the 5th IAS conference on HIV pathogenesis, treatment, and prevention; 2009 [abstract LBPEB06].
21. Lechelt M, Lyons F, Clarke A, Magaya V, Issa R, de Ruiter A. Human placental transfer of atazanavir: a case report. AIDS 2006;20(January (2)):307.
22. Chappuy H, Treluyer JM, Rey E, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2004;191:558-62. (Pubitemid 39178714)
23. Ceccaldi PF, Gavard L, Mandelbrot L, et al. Functional role of P-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. Obstet Gynecol Int 2009;1-6.